

Validated for a wide range of biologics¹⁻³



Family of serum monitoring tests may help you optimize inflammatory bowel disease (IBD) clinical response:

▶ Uniquely measures both serum drug and antidrug antibody levels anytime during treatment^{1,2}

▶ Overcomes limitations of drug-sensitive assays that cannot measure both serum drug and antidrug antibody levels in the presence of drug^{1,2}

▶ Provides critical information that helps you:

- Interpret an IBD patient's clinical response
- Tailor your treatment plan accordingly
- Avoid potentially unnecessary dose intensification in patients with antidrug antibodies or symptoms that are not due to IBD

▶ Proven use in multiple clinical studies⁴⁻¹¹

▶ Confidence of over 100,000 patient experiences since 2012



VALIDATED
for use with¹⁻³:

- ✓ Adalimumab
- ✓ Infliximab/infliximab biosimilars
- ✓ Ustekinumab
- ✓ Vedolizumab

The image shows a screenshot of the PROMETHEUS Anser test requisition form. The form is divided into several sections: SAMPLE COLLECTION INFORMATION, PROVIDER/ACCOUNT INFORMATION, PATIENT INFORMATION (REQUIRED), and TEST INFORMATION (REQUIRED). There are checkboxes for selecting the appropriate test to be performed, including PROMETHEUS Anser ADA, IFX, UST, VDZ, and Monitr™ Crohn's Disease. The form also includes fields for patient name, date of birth, sex, and insurance information.

PLEASE PROVIDE ALL REQUIRED BILLING INFORMATION FOR EACH TEST ORDERED.

- PROMETHEUS[®] Anser[®] ADA - #3170**
Simultaneously measures **adalimumab (ADA)** and antibodies to adalimumab (ATA) levels in serum.
- PROMETHEUS[®] Anser[®] IFX - #3150**
Simultaneously measures **infliximab (IFX)/infliximab biosimilar** and antibodies to infliximab (ATI) levels in serum.
SELECT MEDICATION: REMICADE[®] (INFLIXIMAB) INFLIXIMAB BIOSIMILAR
Anser IFX has been validated for use in patients treated with infliximab biosimilars.
- PROMETHEUS[®] Anser[®] UST - #3190**
Simultaneously measures **ustekinumab (UST)** and antibodies to ustekinumab (ATU) levels in serum.
- PROMETHEUS[®] Anser[®] VDZ - #3180**
Simultaneously measures **vedolizumab (VDZ)** and antibodies to vedolizumab (ATV) levels in serum.
- PROMETHEUS[®] Monitr[™] Crohn's Disease - #7300**
13 biomarkers to assess mucosal healing in Crohn's disease patients. I acknowledge this patient has Crohn's disease.
Current Medication: _____

Exceptional patient support



Convenient mobile phlebotomists

Scheduling a patient appointment with a mobile phlebotomist* is easy:

1. Fully complete the new PROMETHEUS® Anser® Test Requisition Form** and give it to your patient.
2. Make a copy of both the front and back of your patient's insurance card for the patient to give to the mobile phlebotomist.
3. Instruct your patient to call Client Services at **888-423-5227, Option 3**, to schedule an appointment with a mobile phlebotomist.
4. Remind your patient to give the completed Anser® Test Requisition Form to the mobile phlebotomist, along with the copy of the front and back of your patient's insurance card.

[Learn more at anserifx.com/schedule-blood-draw.aspx](http://anserifx.com/schedule-blood-draw.aspx)

*Contracted by Prometheus to draw blood and process serum specifically for Anser tests.

Call Client Services at **888-423-5227, Option 3, to obtain new Anser Test Requisition Forms. Do not use older Prometheus blood draw order forms.

References: 1. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. *J Immunol Methods*. 2012;382(1-2):177-188. 2. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. *J Pharm Biomed Anal*. 2013;78-79:39-44. 3. Data on file. Prometheus Laboratories Inc. 4. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. *Clin Gastroenterol Hepatol*. 2017;15(10):1580-1588. 5. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2014;20(10):1708-1713. 6. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. *Inflamm Bowel Dis*. 2014;20(11):1996-2003. 7. Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. *J Crohns Colitis*. 2016;10(5):510-515. 8. Chaparro M, Guerra I, Iborra M, et al. Correlation between adalimumab serum levels and remission after the induction phase in Crohn's disease patients. *Gastroenterology*. 2015;148(4)(suppl1):S-107-S-108. 9. Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. *Gut*. 2016;65(7):1126-1131. 10. Velayos FS, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. *Gastroenterology*. 2013;144(5)(suppl 1):S-91. 11. Yarur AJ, Deshpande AR, Sussman DA, et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. *Gastroenterol Hepatol*. 2013;9(8)(suppl 4):6.

PROMETHEUS, the Link Design, For the person in every patient, Anser, and the Anser design mark are registered trademarks of Société des Produits Nestlé S.A. Vevey, Switzerland.

©2018 Société des Produits Nestlé S.A. Vevey, Switzerland. All rights reserved. ADA18006 05/18

A Nestlé Health Science Company

Prometheus diagnostic services provide important information to aid in the diagnosis and management of certain diseases and conditions. How this information is used to guide patient care is the responsibility of the physician.

Assays and methods within these tests may be covered by one or more US pending or issued patents. For details, please go to www.prometheuslabs.com. For global inquiries, please contact global@prometheuslabs.com.



9410 Carroll Park Drive
San Diego, CA 92121
888-423-5227 • 858-824-0896 fax

www.prometheuslabs.com